Stem cells are at the forefront of modern medicine and are expected to revolutionize both the human and veterinary healthcare industries. Currently, a major obstacle to the field is the time-consuming and costly technical time spent growing and maintaining various stem cell populations. The degree of contamination with non-stem cells, ability of the stem cells to thrive and grow, and quality of the stem cells depends largely on the skill of the technician.
The goal of the current research is to design an injectable polymer-lipid (Pol.i) formulation to treat ovarian cancer. The PoLi drug delivery system is a hiocompatible and biodegradable, physically cross-linked gel that has the potential to provide dramatic improvements in the treatment of ovarian cancer. It is formulated as an injectable gel (all components are safe for humans) which is then loaaded with active chemotherapy drugs such as the commercially available paclitaxel.
This project will profile the use of new drugs of rheumatoid arthritis, in a population-based sample. Potential differences in the use of these agents will be examined to identify discrepancies in drug use patterns across demographics, which could be addressed through targeted strategies. Our proposal is timely in terms of increasing attention on the part of policy-makers regarding "better, more coordinated evaluation of drug safety and effectiveness" and targeted intitiatives to increase knowledge about the safety and effectiveness of drugs in population-based samples.
Amphotericin B is the most effective, and frequently the only treatment available for a number of life-threatening diseases, including systemic fungal infections and visceral leishmaniasis. The drawbacks of today’s amphotericin B treatment are toxicity and the need to administer the drug intravenously in hospital settings. The need for intravenous administration is due to poor absorption of the drug following oral administration and greatly increases the costs of the therapy and complications associated with intravenous admnistration.
In partnership with Labopharm, a leading company in optimizing the performance of small molecule drugs, a complete pharmacokinetic (PK) study of three new formulations of a commercially available drug will be performed. This study will be conducted in order to choose the most appropriate formulation in terms of bioavailability and absorption rate. Pharmacokinetics parameters of the drug will be estimated using different methods. Mechanisms of drug absorption, distribution, and elimination will also be identified.
Pharmaceuticals are among the most commonly used and important healthcare treatments in Canada. Third party healthcare payers, such as provincial departments of health and private insurers such as Blue Cross and Green Shield, use a variety of tools and techniques to balance the access, cost and quality of medications. Collectively, these tools and techniques are known as drug policies and they include things such as formulary restrictions, prior authorization forms and patient co-payments and deductibles.
Schizophrenia is a complex neurodevelopmental disorder that affects approximately 1% of the population worldwide. Although research on schizophrenia is ongoing, little is still known about its origin. Schizophrenia is thought to result from a combination of genetic and environmental factors that ultimately lead to decreased brain volume and cortical thickness changes in energy metabolism or altered synaptic functioning.